Regeneron Pharmaceuticals (REGN) Total Liabilities (2009 - 2026)

Regeneron Pharmaceuticals has reported Total Liabilities for 18 years, with the latest figure at $10.0 billion in Q2 2026.

• On a quarterly basis, Total Liabilities rose 21.0% year-over-year to $10.0 billion in Q2 2026; TTM through Jun 2026 was $10.0 billion, a 21.0% increase from a year earlier, with the FY2025 full-year figure at $9.3 billion, up 10.66% from the prior year.
• Total Liabilities was $10.0 billion for Q2 2026 at Regeneron Pharmaceuticals, up from $9.4 billion in the prior quarter.
• The five-year high for Total Liabilities was $10.0 billion in Q2 2026, with the low at $6.2 billion in Q3 2022.
• Average Total Liabilities over 5 years is $7.8 billion, with a median of $7.6 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Total Liabilities dropped 2.72% in 2022, then climbed 21.0% in 2026.
• Over 5 years, Total Liabilities stood at $6.6 billion in 2022, then advanced by 8.5% to $7.1 billion in 2023, then climbed by 18.27% to $8.4 billion in 2024, then grew by 10.66% to $9.3 billion in 2025, then climbed by 7.71% to $10.0 billion in 2026.
• The last three Total Liabilities figures came in at $10.0 billion (Q2 2026), $9.4 billion (Q1 2026), and $9.3 billion (Q4 2025), per Business Quant data.